Plain-English translation of NCT05059158 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how the brain accumulates and removes harmful proteins called amyloid-beta that build up in Alzheimer's disease. This study will use advanced imaging scans, brain fluid samples, and sleep monitoring to map out the different ways the brain naturally clears these proteins. By studying people at different stages of memory loss, scientists hope to identify new targets for future treatments.
Alzheimer's disease causes proteins to build up in the brain, but doctors don't fully understand all the pathways the brain uses to remove them. Better understanding these clearance mechanisms could lead to new treatments that help slow or prevent memory loss.
You likely qualify if…
You likely don't qualify if…
You will visit the research center for detailed clinical assessments including brain imaging (MRI and PET scans), tests of thinking and memory, and a sample of fluid around your brain and spine. You will also wear a small device to track your sleep patterns. The study involves one visit with multiple tests on the same day; there are no planned follow-up visits in this phase of the research.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Germany
Sponsor
Ludwig-Maximilians - University of Munich
Enrollment target
~60 participants
Started
June 2021
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
50 Years – 85 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Robert Perneczky, Prof.Dr.med.
Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.